Dopamine and Depression: Clinical Considerations

<p>This podcast features a discussion on the need to highlight anhedonia and anergia as core symptoms of depression. We also cover the clinical utility of MAOIs in treating patients with melancholic or biological depression and Parkinson's disease.</p> <p>Guest: Ken Gillman, M.D.;<br /> Interviewer: Wegdan Rashad, M.D.<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC108"> Learn more about Premium Membership here</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/dopamine-and-depression-clinical-considerations-interview-2599?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC108"> <strong>Earn 0.5 CMEs: Dopamine and Depression: Clinical Considerations - Interview with Ken Gillman, M.D.</strong></a></li> </ul>